125 related articles for article (PubMed ID: 14991931)
1. Salvage therapy for hepatocellular carcinoma with thalidomide.
Wang TE; Kao CR; Lin SC; Chang WH; Chu CH; Lin J; Hsieh RK
World J Gastroenterol; 2004 Mar; 10(5):649-53. PubMed ID: 14991931
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial.
Patt YZ; Hassan MM; Lozano RD; Nooka AK; Schnirer II; Zeldis JB; Abbruzzese JL; Brown TD
Cancer; 2005 Feb; 103(4):749-55. PubMed ID: 15660400
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
4. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.
Chiou HE; Wang TE; Wang YY; Liu HW
World J Gastroenterol; 2006 Nov; 12(43):6955-60. PubMed ID: 17109516
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression.
Schwartz JD; Sung M; Schwartz M; Lehrer D; Mandeli J; Liebes L; Goldenberg A; Volm M
Oncologist; 2005 Oct; 10(9):718-27. PubMed ID: 16249352
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
8. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY; Brophy N; Fisher GA; So S; Biggs C; Yock TI; Levitt L
Cancer; 2005 Jan; 103(1):119-25. PubMed ID: 15565573
[TBL] [Abstract][Full Text] [Related]
10. Low-dose thalidomide treatment for advanced hepatocellular carcinoma.
Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL
Oncology; 2003; 65(3):242-9. PubMed ID: 14657598
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
12. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
13. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Ang SF; Tan SH; Toh HC; Poon DY; Ong SY; Foo KF; Choo SP
Am J Clin Oncol; 2012 Jun; 35(3):222-7. PubMed ID: 21378539
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis.
Chen YY; Yen HH; Chou KC; Wu SS
World J Gastroenterol; 2012 Feb; 18(5):466-71. PubMed ID: 22346253
[TBL] [Abstract][Full Text] [Related]
15. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Ch'ang HJ; Hsu C; Chen CH; Chang YH; Chang JS; Chen LT
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):817-25. PubMed ID: 21277098
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Lee KD; Hsiao CH; Lu YS; Huang CC; Shen YC; Hsu CH; Cheng AL
Oncology; 2012; 82(1):59-66. PubMed ID: 22310088
[TBL] [Abstract][Full Text] [Related]
18. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
Hsu WC; Chan SC; Ting LL; Chung NN; Wang PM; Ying KS; Shin JS; Chao CJ; Lin GD
Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy combined with TACE - more beneficial therapeutic effect in HCC.
Wang Z; Li Z
Aliment Pharmacol Ther; 2010 May; 31(10):1153-4. PubMed ID: 20518755
[No Abstract] [Full Text] [Related]
20. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
Lee CC; Wu YH; Chung SH; Chen WJ
Oncologist; 2006 Jan; 11(1):87-8; author reply 89. PubMed ID: 16401719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
